Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers November 20, 2017
Pharmacy Choice - News - Pharmaceutical Development - November 20, 2017

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

11/20/17 - "Composition and Method for Treatment of Depression and Psychosis in Humans" in Patent Application Approval Process (USPTO 20170312275)
By a News Reporter-Staff News Editor at Pharma Business Week A patent application by the inventor Javitt, Daniel C., filed on July 16, 2017, was made available online on November 9, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to Glytech LLC. "Diagnosis of schi
11/20/17 - "Low Dose Pharmaceutical Composition" in Patent Application Approval Process (USPTO 20170312254)
By a News Reporter-Staff News Editor at Pharma Business Week A patent application by the inventors MALHOTRA, Geena; PURANDARE, Shrinivas Madhukar, filed on July 14, 2017, was made available online on November 9, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application has not been assi
11/20/17 - "Mission: Cure" Launched to Harness Innovative Financing and Impact Investing to Cure Disease; Pioneers New Approach by Attacking Pancreatic Disease
By a News Reporter-Staff News Editor at Clinical Trials Week The new nonprofit Mission: Cure will convene the world's leading pancreatic experts at the American Pancreatic Association meeting in San Diego on November 10th to devise a 10- year plan to cure chronic pancreatitis, a painful and costly pancreatic disease, using an innovative financing
11/20/17 - "Pharmaceutical Composition and Use Thereof" in Patent Application Approval Process (USPTO 20170312234)
By a News Reporter-Staff News Editor at Clinical Trials Week A patent application by the inventor Lin, Jung-Yaw, filed on May 2, 2016, was made available online on November 9, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to National Taiwan Normal University.
11/20/17 - "Pyrazolo[1,5-A]pyridine Compounds and Use Thereof" in Patent Application Approval Process (USPTO 20170313697)
By a News Reporter-Staff News Editor at Clinical Trials Week A patent application by the inventors Lu, Xiaoyun; Tang, Jian; Ding, Ke; Zhang, Tianyu; Zhang, Xiantao; Tu, Zhengchao; Wu, Tian; Wan, Junting; Cao, Yuanyuan; He, Shengjiang, filed on August 13, 2015, was made available online on November 9, 2017, according to news reporting originating
11/20/17 - Acceleron Announces Appointment of Dr. Karen Smith to its Board of Directors and Departure of Terrance McGuire
CAMBRIDGE, Mass.- Acceleron Pharma Inc. today announced the appointment of the experienced biopharmaceutical executive, Karen Smith, M.D., Ph.D., to its board of directors and the departure of Terrance McGuire, effective November 15, 2017. Dr. Smith currently serves as Executive Vice President, Global Head R&D, and Chief Medical Officer of Jazz Pha
11/20/17 - AcelRx Pharmaceuticals Reports Publication of Manuscript Evaluating Sufentanil Sublingual Tablets for Moderate-to-Severe Acute Pain in the Emergency...
By a News Reporter-Staff News Editor at Clinical Trials Week AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, reported the publication of a manuscript analyzing sufentanil sublingual tablet 30 mcg for...
11/20/17 - Adocia Reports Topline Results of BioChaperone Glucagon Phase 1 Study
ADOCIA a clinical stage biopharmaceutical company focused on diabetes treatment with innovative formulations of approved proteins, today announced top-line results of a Phase 1 study of BioChaperone Glucagon, its aqueous formulation of human glucagon. Stanislav Glezer, Adocia s Chief Medical Officer. We are currently selecting an easy-to-u
11/20/17 - Alkermes Calls for Impartial National Review of Scientific Data Supporting the Use of FDA-Approved Treatment Options for Opioid Dependence
By a News Reporter-Staff News Editor at Biotech Business Week Amid one of the nation's deadliest and most significant public health crises of our time, Alkermes is calling for a formal review by the National Institutes of Health of data related to all FDA- approved medication-assisted treatment options for opioid dependence. "In the face of this
11/20/17 - Alnylam Announces Successful Outcome Following FDA Type A Meeting to Discuss Fitusiran Program in Hemophilia
By a News Reporter-Staff News Editor at Clinical Trials Week Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced a successful Type A meeting with the U.S. Food and Drug Administration where alignment was achieved on safety measures and a risk mitigation strategy to enable resumption of dosing in clinical studies with f
11/20/17 - Alnylam Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Patisiran for the Treatment of Hereditary ATTR Amyloidosis
CAMBRIDGE, Mass.- Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today announced the company has initiated submission of a rolling New Drug Application to the U.S. Food and Drug Administration for patisiran, an investigational RNAi therapeutic targeting transthyretin, for the treatment of hereditary ATTR amyloidosis.
11/20/17 - Alnylam: FDA Grants Breakthrough Therapy Designation For Patisiran
WASHINGTON- Alnylam Pharmaceuticals, Inc., a RNAi therapeutics company, announced Monday that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation or BTD for patisiran, an investigational RNAi therapeutic targeting transthyretin. Patisiran previously received Fast Track Designation in the U.S., and was recently granted
11/20/17 - Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 Biosimilar Bevacizumab For The Treatment Of Certain Types Of Cancer
By a News Reporter-Staff News Editor at Biotech Business Week Amgen and Allergan plc. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the Marketing Authorization of ABP 215, a biosimilar to Avastin . "ABP 215 has the potential to provide healthcare profession
11/20/17 - Amgen Receives Positive CHMP Opinion To Expand Use Of Nplate romiplostim In Pediatric Patients With Chronic Immune Thrombocytopenic Purpura
By a News Reporter-Staff News Editor at Pharma Business Week Amgen announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion to expand the current indication for Nplate to include the treatment of chronic immune thrombocytopenic purpura for patients one year of age and old
11/20/17 - Artemis Therapeutics Receives Orphan Drug Designation From U.S. Food And Drug Administration For Artemisone For The Treatment Of Malaria
By a News Reporter-Staff News Editor at Pharma Business Week Artemis Therapeutics, Inc.,, a pharmaceutical company developing new therapies for the treatment of life-threatening infectious diseases, announced that the U.S. Food and Drug Administration granted orphan drug designation for Artemisone, the Company's lead product candidate, for the...
11/20/17 - Batu Biologics Receives FDA Clearance for First Multi-Pronged Immunotherapy Targeting the Blood Vessels that Feed Cancer
By a News Reporter-Staff News Editor at Cancer Vaccine Week Batu Biologics, an immuno-oncology company dedicated to the development of its tumor-angiogenesis targeting immune therapy, ValloVax?, has received an Investigational New Drug approval from the U.S. Food and Drug Administration allowing Batu to proceed with Phase 1 clinical trials.
11/20/17 - Bayer and PeptiDream to identify new active substance candidates through novel peptide-based screening technology
Berlin- Bayer and PeptiDream, a public Japanese biopharmaceutical company, have entered into a global drug discovery collaboration across multiple therapeutic areas and target classes. Under the agreement, Bayer and PeptiDream will work to identify new compounds for difficult-to-address drug targets by using PeptiDream's proprietary Peptide...
11/20/17 - Biocon rallies 4% after Bengaluru unit gets cleared by US FDA [India Infoline News Service]
The US FDA had audited the company s aseptic drug facility between May 25 and June 3 The US Food and Drug Administration issued an Establishment Inspection Report in relation to the inspection of Biocon s Bengaluru unit. The US FDA had previously issued a report in which they issued 10 observations on Biocon s Bengaluru plant. Biocon Ltd i
11/20/17 - Biohaven Completes Enrollment in the First of Two Pivotal Phase 3 Clinical Trials of Rimegepant
NEW HAVEN, Conn.- Biohaven Pharmaceutical Holding Company Ltd. announced that it is completing enrollment today in the first of its two registrational Phase 3 clinical trials, Study BHV3000-301, to establish the safety and efficacy of orally-dosed rimegepant. Study BHV3000-301 has enrolled over 1,400 subjects since July 2017. Vlad Coric, M.D., Chie
11/20/17 - BioLineRx Announces Partial Results of BL-8040 COMBAT Study Accepted for Presentation at ASCO 2018 Gastrointestinal Cancers Symposium
BioLineRx Ltd., a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that an abstract with partial results from the monotherapy portion of BL-8040's Phase 2 a COMBAT study in pancreatic cancer was accepted for presentation at the ASCO 2018 Gastrointestinal Cancers Symposium, to take place January 18-20, 201
11/20/17 - BiondVax and NIH Sign Clinical Trial Agreement for a Phase 2 Trial in the U.S. with BiondVax's Universal Flu Vaccine
NESS ZIONA, Israel, November 20, 2017/ PRNewswire/. BiondVax Pharmaceuticals Ltd. today announced the signing of the clinical trial agreement for a Phase 2 clinical trial with the National Institute of Allergy and Infectious Diseases of the U.S. National Institutes of Health. Tamar Ben-Yedidia explained, "Along with our successful European Union
11/20/17 - BioPharmX Receives Concurrence from FDA on Phase 3 Acne Study Plans
By a News Reporter-Staff News Editor at Clinical Trials Week BioPharmX Corporation, a specialty pharmaceutical company developing products for the dermatology market, announces it has received positive feedback from the U.S. Food and Drug Administration regarding design of its planned phase 3 clinical trial for BPX-011, the company's topical...
11/20/17 - Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab anti-CSF-1 receptor antibody with Opdivo nivolumab in Patients...
Bristol-Myers Squibb and Five Prime Present Phase 1 a/1b Data Evaluating Cabiralizumab anti-CSF-1 receptor antibody with Opdivo nivolumab in Patients with Advanced Solid Tumors. By a News Reporter-Staff News Editor at Cancer Vaccine Week Bristol-Myers Squibb Company and Five Prime Therapeutics, Inc. announced preliminary results from a dose...
11/20/17 - Cardiome to Present at the 29th Annual Piper Jaffray Healthcare Conference
-Cardiome Pharma Corp., a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected hospital drugs, today announced that Mr. Justin Renz, Chief Financial Officer of Cardiome, will present at the 29th Annual Piper Jaffray Healthcare Conference. Cardiome Pharma Corp. is a revenue-generating, specialty...
11/20/17 - Cellectar Biosciences to Present at the 10th Annual LD Micro Main Event
Cellectar Biosciences, a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it will be presenting at the 10th Annual LD Micro Main Event on Tuesday, December 5th at 8:30 AM PT/ 11:30 AM ET. About Cellectar Biosciences, Inc. Cellectar Biosc
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415